May 28, 2025
TransCode Therapeutics Appoints Dr. Phillip D. Zamore to Science Advisory Board
May 05, 2025
TransCode Therapeutics Announces Effective Date for 1-for-28 Reverse Stock Split
Apr 21, 2025
TransCode Therapeutics, Inc. Announces Adjournment of Special Meeting and Information for Adjourned Special Meeting
Apr 16, 2025
An Open Letter to Shareholders of TransCode Therapeutics, Inc. Asking Stockholders to Vote FOR the Proposal to Authorize a Reverse Stock Split if Necessary
Mar 27, 2025
TransCode Therapeutics Announces Initial Dosing in Fourth Cohort of Phase 1 Clinical Trial with TTX-MC138
Mar 25, 2025
TransCode Therapeutics, Inc. Announces Closing of Registered Direct Offering
Mar 23, 2025
TransCode Therapeutics, Inc. Announces Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Mar 13, 2025
TransCode Therapeutics Announces Safety Review Committee Approval to Open Fourth Cohort in Phase I/II Clinical Trial
Feb 25, 2025
TransCode Therapeutics, Inc. Announces Results of Special Meeting
Feb 06, 2025
TransCode Therapeutics Announces Completion of Cohort 3 Initial Dosing with Lead Candidate in Phase 1 Clinical Trial
Feb 04, 2025
TransCode Therapeutics, Inc. Announces Adjournment of Special Meeting and Information for Adjourned Special Meeting
Jan 14, 2025
TransCode Therapeutics Announces First Patient Dosed in Third Cohort with Lead Candidate in Phase 1 Clinical Trial
Dec 18, 2024
TransCode Therapeutics Announces Safety Review Committee Approval of Opening Third Cohort and Preliminary Results from First Cohort in Phase 1 TTX-MC138 Clinical Trial